

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	1	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/712,781	11/12/2003		Ping Jiang	312762004200	7795
25225	7590	09/28/2006	EXAMINER		INER
MORRISC 12531 HIGH		ERSTER LLP	KETTER,	KETTER, JAMES S	
SUITE 100					PAPER NUMBER
SAN DIEG	O, CA 9	2130-2040	1636		
				DATE MAILED: 09/28/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant/s)					
		Applicant(s)					
Office Action Summary	10/712,781 Examiner	JIANG ET AL.					
,		Art Unit					
The MAII ING DATE of this communication and	James S. Ketter	1636					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1)⊠ Responsive to communication(s) filed on <u>5 Jul</u>	lv 2006.						
	action is non-final.						
· <u>-</u>	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under E							
Disposition of Claims							
4)⊠ Claim(s) <u>1-6 and 10</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>1-6 and 10</u> is/are rejected.							
<u> </u>	7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) □ acc	epted or b) \square objected to by the $\mathfrak l$	Examiner.					
Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correct	tion is required if the drawing(s) is obj	jected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
<u> </u>	a) ☐ All b) ☐ Some * c) ☐ None of:						
 Certified copies of the priority document 	1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s)							
Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Surmary Paper No(s)/Mail Da						
3) 🔯 Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) 5) 🔲 Notice of Informal Patent Application (PTO-152)							
Paper No(s)/Mail Date <u>2/27/4,3/9/5,9/1/6</u> .	6) Other:						

Art Unit: 1636

Applicant's election without traverse of Group I, claims 1-6 and 10, in the reply filed on 5 July 2006 is acknowledged.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-6 and 10 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The following factors have been considered in the present rejection:

The nature of the invention. The instant invention is drawn to a method that recites the sample of the tissue cultured "in" a three-dimensional collagen sponge-gel culture. As set forth below in the rejection under 35 USC § 112, second paragraph, the term "in" is indefinite in the present context. As a result, the claim may be interpreted as including embodiments wherein the tissue is intertwined with the strands of collagen which form the sponge-like structure of the gel, i.e., the tissue is found extended through the pores of the sponge-gel.

The amount of direction or guidance present in the specification, and the presence or absence of working examples. The specification does not set forth any method by which the

sample of tissue would penetrate the pores of the sponge-gel and still maintain its structure as a tissue or tissue sample.

The state of the prior art. There is no teaching in the prior art toward the growth of tissue into such a matrix while maintaining its tissue structure.

The predictability or unpredictability of the art. As set forth in, for example, paragraph [0008] of the present specification, maintenance of the sample in tissue form solves the problem of RNA degradation. However, it is not clear to what extent the tissue may be disrupted or changed to a more cell culture-like form and preserve this advantage.

Conclusion. Neither the specification nor the art teaches how to practice those embodiments of the invention wherein the tissue is found extended through the pores of the sponge-gel. Even if through experimentation a way were found to create such a structure, it is not apparent that the tissue-like characteristics of the tissue sample would be preserved to allow for use or function of the invention in the manner disclosed.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-6 and 10 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 recites "an intact sample of said tissue cultured in a three-dimensional collagen sponge-gel culture." However, it is not clear whether "in" in the present usage means that the

Application/Control Number: 10/712,781

Art Unit: 1636

cells of the tissue sample are intertwined among the fibers which form the sponge-like matrix of

the gel, or whether the claim is limited to the presence of the sample only between pieces or

layers of the sponge-gel without such intertwining. The specification does not offer a clear

definition.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to James S. Ketter whose telephone number is 571-272-0770. The

examiner can normally be reached on Monday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Remy Yucel can be reached on 571-272-0781. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would

like assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

JSK

19 September 2006

JAMES KETTER

Page 4